Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed the day trading at $53.30 up 1.66% from the previous closing price of $52.43. In other words, the price has increased by $1.66 from its previous closing price. On the day, 0.54 million shares were traded. RARE stock price reached its highest trading level at $54.41 during the session, while it also had its lowest trading level at $52.505.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.39 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 2.14 whereas as Long-Term Debt/Eq ratio is at 2.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 03 ’24 when KAKKIS EMIL D sold 20,000 shares for $55.85 per share. The transaction valued at 1,117,000 led to the insider holds 2,223,985 shares of the business.
Huizenga Theodore Alan sold 91 shares of RARE for $5,113 on Sep 03 ’24. The SVP, Chief Accounting Officer now owns 41,551 shares after completing the transaction at $56.19 per share. On Sep 03 ’24, another insider, KAKKIS EMIL D, who serves as the Officer of the company, bought 20,000 shares for $55.85 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4912404992 and an Enterprise Value of 5071651840. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.21 while its Price-to-Book (P/B) ratio in mrq is 11.35. Its current Enterprise Value per Revenue stands at 10.537 whereas that against EBITDA is -9.834.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is -1.95%, while the 200-Day Moving Average is calculated to be 12.94%.
Shares Statistics:
Over the past 3-months, RARE traded about 710.89K shares per day on average, while over the past 10 days, RARE traded about 654420 shares per day. A total of 92.17M shares are outstanding, with a floating share count of 86.30M. Insiders hold about 6.36% of the company’s shares, while institutions hold 96.68% stake in the company. Shares short for RARE as of 1726185600 were 3614532 with a Short Ratio of 5.08, compared to 1723680000 on 3847176. Therefore, it implies a Short% of Shares Outstanding of 3614532 and a Short% of Float of 4.5.
